BAMF
FOLD

BI Asset Management Fondsmaeglerselskab’s Amicus Therapeutics FOLD Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,494
Closed -$53K – 803
2025
Q1 		$53K Buy
+6,494
New +$60.1K ﹤0.01% 783
2019
Q4 		– Sell
-6,011
Closed -$48K – 365
2019
Q3 		$48K Buy
6,011
+2,369
+65% +$25.7K ﹤0.01% 352
2019
Q2 		$45K Buy
+3,642
New +$46.2K ﹤0.01% 238

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's FOLD Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Amicus Therapeutics (FOLD) in Q2 2025, closing a stake of 6,494 shares — an estimated $53K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in FOLD in Q2 2019 and held it in 3 quarters. The position peaked at $53K in Q1 2025. 272 funds tracked by Wall St. Rank hold FOLD as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Amicus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 6,494 Amicus Therapeutics shares in Q2 2025, an estimated $53K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Amicus Therapeutics in Q2 2019 and held it in 3 quarters.
  • BI Asset Management Fondsmaeglerselskab's Amicus Therapeutics position peaked at $53K in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.